Savant Capital’s bluebird bio BLUE Stock Holding History

Savant Capital’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,177	Closed	-$42.9K	–	1397
2024 Q2	$42.9K	Buy	+2,177	New	+$43.6K	﹤0.01%	1244

Other funds holding BLUE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Savant Capital's BLUE Position: Q3 2024 in Review

Savant Capital sold out of bluebird bio (BLUE) in Q3 2024, closing a stake of 2,177 shares — an estimated $42.9K sold.

Savant Capital first reported a position in BLUE in Q2 2024 and held it in 1 quarter. The position peaked at $42.9K in Q2 2024. 140 funds tracked by Wall St. Rank hold BLUE as of Q3 2024.

Savant Capital reported no remaining bluebird bio position as of Q3 2024 after selling out during the quarter.
Savant Capital sold 2,177 bluebird bio shares in Q3 2024, an estimated $42.9K.
Savant Capital first reported a position in bluebird bio in Q2 2024 and held it in 1 quarter.
Savant Capital's bluebird bio position peaked at $42.9K in Q2 2024.
140 funds tracked by Wall St. Rank held bluebird bio as of Q3 2024.

Based on Savant Capital's 13F filing for Q3 2024, filed 4 Nov 2024.